Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27831566)

Published in Cell Death Dis on November 10, 2016

Authors

Álvaro de Mingo1, Estefanía de Gregorio1, Anna Moles2, Núria Tarrats1, Anna Tutusaus1, Anna Colell1, Jose C Fernandez-Checa1,3, Albert Morales1, Montserrat Marí1

Author Affiliations

1: Department of Cell Death and Proliferation, IIBB-CSIC/IDIBAPS, Barcelona, Catalonia, Spain.
2: Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.
3: Research Center for Alcoholic Liver and Pancreatic Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

Articles cited by this

Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J (2004) 11.00

The Sir2 family of protein deacetylases. Annu Rev Biochem (2004) 9.28

Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39

Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab (2009) 5.02

The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20

Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest (2000) 3.58

NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23

Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med (2015) 2.59

Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55

Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des (2007) 2.26

Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18

CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03

Cathepsin cysteine proteases in cardiovascular disease. FASEB J (2007) 1.92

Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73

Lysosomal involvement in cell death and cancer. Biochim Biophys Acta (2008) 1.69

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal (2013) 1.65

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol (2012) 1.59

Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47

Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol (2001) 1.39

Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol (2010) 1.24

Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology (2009) 1.23

Cathepsin cleavage of sirtuin 1 in endothelial progenitor cells mediates stress-induced premature senescence. Am J Pathol (2012) 1.16

Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1). Exp Cell Res (2001) 1.11

75-kd sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheum (2012) 1.09

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit (2011) 1.03

New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential therapeutics. CNS Neurol Disord Drug Targets (2008) 1.01

Kinetics of interleukin-2 and interleukin-6 synthesis following major mechanical trauma. J Surg Res (1990) 0.98

Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol (2013) 0.95

Nuclear translocation of mitochondrial cytochrome c, lysosomal cathepsins B and D, and three other death-promoting proteins within the first 60 minutes of generalized seizures. J Neurosci Res (2010) 0.92

NF-kappaB signalling: embracing complexity to achieve translation. J Hepatol (2009) 0.91

Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S. Biochem Biophys Res Commun (2000) 0.90

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol (2013) 0.81

Hepatoprotective effects of cathepsin B inhibitor on acute hepatic failure induced by lipopolysaccharide/D-galactosamine in mice. Hepatobiliary Pancreat Dis Int (2013) 0.77